Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... is equally effective and significantly better tolerated than IM progesterone for luteal phase support in In Vitro Fertilization and Embryo Transfer (IVF-ET) cycles. According to the ... A New Therapy) Study, a randomized, double blind, placebo controlled 450-patient Phase III clinical trial evaluating the ability of PROCHIEVE® 8% (progesterone gel) to reduce ...
2009 NOV 23 ... The Bend Memorial Clinic is recruiting patients for a PhaseIII lung cancer trial aimed at preventing the disease's recurrence in previously ...
2009 NOV 23 ... immune defenses. Its lead product is Multikine=AE which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a treatment for ...
2009 NOV 23 ... Celsion's Chief Executive Officer. "We have expanded the HEAT trial (ThermoDox global PhaseIII HCC study) to the Asia Pacific region where the incidence of primary liver cancer is ...
2009 NOV 23 ... the treatment of depression in the first quarter of calendar 2010, and will initiate our PhaseIII program for Stedivaze for cardiac stress testing, shortly. During the quarter, we ... was attributable primarily to the concluding activities related to the vilazodone safety trial, Phase III clinical program and initial preparations for the NDA submission, which is ...
2009 NOV 23 ... Curemark now is enrolling patients at 12 sites across the country in PhaseIII clinical trials for CM-AT, one of the first therapies targeted to address the ... Biotech Business, Autism, Biotechnology Business, Biotechnology Company, Clinical Trial Research, Developmental Disabilities, Drug Development, Drug Discovery, Neurology, ...
2009 NOV 23 ... into the study and D-Pharm may elect to fund recruitment of additional patients. The Phase III trial in China will be performed in compliance with the Food and Drug Administration (FDA) ...
2009 NOV 28 ... according to the principles of MRC Good Clinical Practice (GCP) Guidelines and CTRU Phase III Trial Standard Operating procedures."Christie and colleagues published their ...
2009 NOV 23 ... intraepithelial neoplasia (PIN): The last patient will complete the toremifene 20 mg PhaseIII high grade PIN clinical trial in the first quarter of 2010. GTx plans to announce ...
2009 NOV 23 ... the largest and fastest-growing therapy class, with more than 130 products currently in PhaseIII clinical trials or pre-approval stage. "IMS Oncology Quantifier brings ... ggatyas@us.imshealth.com Keywords: Cancer, Clinical Trial Research, Oncology, Pharmaceuticals, Therapy, Treatment. This article was ...
2009 NOV 23 ... OSteoporosis (TROPOS) trials, two major 3-year multinational placebo-controlled PhaseIII randomized clinical trials. In SOTI, SR treatment reduced the risk of vertebral ... England. Keywords: France, Lille, Osteoporosis Risk Factors, Bone, Clinical Trial Research, Hip Fractures, Osteoporosis, Rheumatology, Therapy, Treatment. ...
2009 NOV 23 ... between LVEF and SRS (r=-0.31, P<.0001) and there were stronger correlations between phase SD and SRS (r=0.66, P<.0001) as well as phase SD and LVEF (r=-0.50, P<.0001). with ... (r=0.66, P<.0001) as well as phase SD and LVEF (r=-0.50, P<.0001). with NYHA class III symptoms had more severe and significant degrees of dyssynchrony (median phase SD 54 ... unknown." "This article addresses the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) gated SPECT imaging (gSPECT) ...
2009 NOV 29 ... The authors assert that health care in the United States is nearing the end of a phase of exploitation and conservation in which rapid growth, specialization and ... to Decrease Antibiotics Used for Self-Medication Among Latino Adults By Arch G. Mainous III, Ph.D., et al Medical University of South Carolina, CharlestonOther Studies ... Controlled Trials Authors frequently change the outcomes of clinical trials between trial registration and publication without explanation or disclosure. Analyzing 110 randomized ...
2009 NOV 23 ... therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018. ... Examination of the CRC pipeline with in-depth clinical and commercial profiles of Phase III candidates Seven major pharmaceutical market sales forecasts for Phase III ... of attainment R&D Approach Key findings Clinical trial design in colorectal cancer (CRC) Patient selection Clinical ...
2009 NOV 23 ... of monoamine oxidase-B follows selegiline. In light of the recent large clinical study (phaseIII ADAGIO) reporting benefits in PD patients, it has been suggested that rasagiline ... Nervous System Disease, Mental Health, Neurodegenerative, Oxidase, Enzymes, Clinical Trial Research, Clinical Trials, Pre-Trials Research, Therapy, Treatment, Pharmaceuticals, ...
2009 NOV 23 ... Australia report. "Blood was collected from 120 patients enrolled in a Phase III trial of maintenance therapy +/-thalidomide after autologous stem cell transplantation. TCR ...
2009 NOV 23 ... being elucidated with the use of animal models or axonal excitability techniques. In the phaseIII Assessment of Proteasome Inhibitor for Extending Remissions trial, it proved that ...
2009 NOV 23 ... a community-focused approach to develop a locally-appropriate SoC in the context of a phaseIII vaginal microbicide trial in Mwanza City, northwest Tanzania. A mobile ...
2009 NOV 23 ... 30, 2008. Increases for both periods were due to the initiation of our oral calcitonin PhaseIII clinical trial. Net loss for the three months ended September 30, 2009 ...
